Get the Stockscreener App
76.75
1.39%
-1.08
After Hours:
76.75
Kiniksa Pharmaceuticals International Plc stock is traded at $76.75, with a volume of 403.45K.
It is down -1.39% in the last 24 hours and up +23.83% over the past month.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.
See More
Previous Close:
$77.83
Open:
$77.32
24h Volume:
403.45K
Relative Volume:
0.55
Market Cap:
$5.99B
Revenue:
$754.05M
Net Income/Loss:
$73.06M
P/E Ratio:
84.59
EPS:
0.9073
Net Cash Flow:
$164.23M
1W Performance:
+0.91%
1M Performance:
+23.83%
6M Performance:
+69.16%
1Y Performance:
+130.62%
1-Day Range:
$75.30
$77.51
1-Week Range:
$75.00
$79.79
52-Week Range:
$32.89
$82.94
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Company Profile
Name
Kiniksa Pharmaceuticals International Plc
Sector
Phone
(781) 431-9100
Address
105 PICCADILLY, SECOND FLOOR, LONDON
Compare KNSA vs TAK, TEVA, HLN, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KNSA
Kiniksa Pharmaceuticals International Plc
|
76.75 | 6.10B | 754.05M | 73.06M | 164.23M | 0.9073 |
TAK
Takeda Pharmaceutical Co Adr
|
17.63 | 55.60B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
36.77 | 42.81B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.70 | 43.16B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
73.79 | 30.39B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
499.73 | 21.95B | 3.17B | 1.29B | 1.01B | 27.09 |
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-19-26 | Initiated | Canaccord Genuity | Buy |
| Sep-29-25 | Initiated | TD Cowen | Buy |
| Mar-13-25 | Initiated | Citigroup | Buy |
| Sep-13-24 | Initiated | Jefferies | Buy |
| May-03-24 | Initiated | Wells Fargo | Overweight |
| Jun-29-20 | Reiterated | BofA Securities | Buy |
| Apr-01-20 | Initiated | BofA/Merrill | Buy |
| Mar-11-19 | Initiated | Barclays | Overweight |
| Dec-12-18 | Reiterated | Wedbush | Outperform |
| Jun-19-18 | Initiated | JMP Securities | Mkt Outperform |
View All
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Latest News
Bank of America Corp DE Boosts Stake in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Kiniksa Pharmaceuticals International, plc Class A Revenue Breakdown – BIVA:KNSA/N - TradingView
KNSA: ARCALYST drives record growth as pipeline advances and patient access, awareness, and satisfaction rise - TradingView
Kiniksa Pharmaceuticals (KNSA) Stock Analysis: A Promising Outlook with 28% Potential Upside - DirectorsTalk Interviews
Kiniksa Pharmaceuticals International, plc Class A Actuals & Estimates (NASDAQ:KNSA) - TradingView
Does Raised 2026 Revenue Guidance Change The Bull Case For Kiniksa Pharmaceuticals International (KNSA)? - simplywall.st
Kiniksa Pharmaceuticals International, plc $KNSA Stake Raised by The Manufacturers Life Insurance Company - MarketBeat
Kiniksa Pharmaceuticals to present at Canaccord Genuity Growth Conference on August 12, 2026 - Pluang
Kiniksa’s Aug. 12 fireside chat will stream live online - Stock Titan
Kiniksa Pharmaceuticals to Present at Canaccord Genuity 46th Annual Growth Conference - globenewswire.com
Kiniksa Pharmaceuticals International PLC (KNSA) Stock News Today - TradingKey
Kiniksa Pharmaceuticals International PLC (KNSA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Kiniksa Pharmaceuticals International, plc $KNSA Shares Sold by Lazard Asset Management LLC - MarketBeat
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
31,391 Shares in Kiniksa Pharmaceuticals International, plc $KNSA Bought by Financial Enhancement Group LLC - MarketBeat
Kiniksa Pharmaceuticals International, plc $KNSA Shares Bought by Janus Henderson Group PLC - MarketBeat
Kiniksa Pharmaceuticals International's (NASDAQ:KNSA) Strong Earnings Are Of Good Quality - 富途牛牛
Kiniksa Pharmaceuticals (KNSA) Stock Analysis: Unlocking A 33.5% Upside Potential - DirectorsTalk Interviews
Dimensional Fund Advisors LP Purchases 128,417 Shares of Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
KNSA Q2 Earnings Call Backs Higher ARCALYST Sales Outlook - The Globe and Mail
Kiniksa Pharmaceuticals International, plc (KNSA) director sells and gifts shares - Stock Titan
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Director G Bradley Cole Sells 3,673 Shares of Stock - MarketBeat
The Goldman Sachs Group Issues Positive Forecast for Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock Price - MarketBeat
KNSA Maintained by Canaccord Genuity -- Price Target Raised to $98 - GuruFocus
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Given New $107.00 Price Target at JPMorgan Chase & Co. - MarketBeat
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Price Target Raised to $98.00 - MarketBeat
Kiniksa Pharmaceuticals International, plc Stock 12‑Month Price Target Raised to $79.62, Implies 25% Upside - TradingView
Stronger Q2 Results And Higher 2026 Outlook Might Change The Case For Investing In Kiniksa (KNSA) - simplywall.st
KNSA Looks 59.8% Overvalued on GF Value™ After Q2 Earnings Surge - GuruFocus
KNSA Looks 58.0% Overvalued on GF Value™ as Shares Surge 22.7% - GuruFocus
KNSA Looks 59.0% Overvalued on GF Value™ as Shares Surge Amid Mi - GuruFocus
Wedbush Raises Price Target on Kiniksa Pharmaceuticals to $99 From $72, Maintains Outperform Rating - marketscreener.com
Kiniksa Pharmaceuticals International Q2 Earnings Call Highlights - Yahoo Finance
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Hits New 52-Week HighWhat's Next? - MarketBeat
KNSA: Record ARCALYST sales and strong pipeline progress drove raised 2026 guidance and cash growth - TradingView
Kiniksa Pharmaceuticals International, plc Provides Earnings Guidance for Year 2026 - marketscreener.com
Kiniksa Pharmaceuticals International, plc (KNSA) Q2 Earnings Match Estimates - Yahoo Finance
KNSA: Q2 2026 delivered 55% YoY ARCALYST sales growth and raised 2026 revenue guidance to $980–$995M - TradingView
Is Kiniksa Pharmaceuticals (KNSA) Overvalued After Q2 Earnings B - GuruFocus
Kiniksa Pharmaceuticals International (KNSA) Reports Q2 2026 Numbers - AlphaStreet
Kiniksa Pharmaceuticals stock rises 2% on raised guidance, revenue beat By Investing.com - Investing.com Nigeria
Earnings Flash (KNSA) Kiniksa Pharmaceuticals Posts Q2 EPS $0.30, vs. FactSet Est of $0.28 - marketscreener.com
Rubric Capital Management LP Acquires 421,347 Shares of Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Kiniksa (Nasdaq: KNSA) boosts 2026 ARCALYST sales view after strong Q2 - Stock Titan
Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution - GlobeNewswire
Kiniksa Pharmaceuticals Announces Q2 2026 Financial Results and Advances Clinical Pipeline Developments - Kalkine Media
KNSA|Kiniksa Pharmaceuticals International PLC|Price:63.560|Chg%:+0.720 - TradingKey
Kiniksa Pharmaceuticals International PLC (KNSA) Cash Flow - TradingKey
Kiniksa Pharmaceuticals International PLC (KNSA) Q2 2026: Everything You Need To Know Ahead Of ... - Yahoo Finance
Kiniksa Pharmaceuticals International PLC (KNSA) Q2 2026: Everyt - GuruFocus
Kiniksa Pharmaceuticals (NASDAQ:KNSA): A High-Growth Stock with Strong Technical Setup - ChartMill
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.79%
5.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):